Examine the Role of Drug Delivery in Toxicology
Complete the form below to unlock access to ALL audio articles.
Research and Markets has announced the addition of "Managing Toxicology for the Future: Improving Predictive Power Through Integrated Technologies, 2nd Edition" to their offering.
About $70 million (20%) of the total R&D costs per drug are spent on ADME/Tox failures.
Preclinical toxicity is one of the major bottlenecks in drug development. In particular, the ability to predict the safety of a drug in the preclinical stage, prior to human testing, has been one of the major bottlenecks in drug development.
Current approaches have serious limitations in their ability to predict toxicity in humans, and thus invite substantial risk not only in terms of patient welfare, but also in terms of the cost of late-stage clinical trial failure.
The integration of traditional approaches to preclinical toxicity assessment will have a major impact on the ability to predict compound behavior in humans, reduce clinical trial failure, and cut both risk and cost in drug development.
Market Analysis Report, Managing Toxicology for the Future: Improving Predictive Power Through Integrated Technologies, discusses the critical challenges associated with ADME/Tox testing during pharmaceutical R&D, including the requirements for:
- New strategies to minimize toxicity-related drug failures aimed at improving R&D productivity and pharmaceutical risk management.
- Breath of expertise in multiple disciplines to deal with a complex and fragmented technology landscape, such as "omics" technologies and in silico approaches.
- Integrative activities that combine new and old approaches to assess drug safety in a highly regulated and risk-aversive environment.
- Industry-wide collaborative efforts to build the necessary research infrastructure for toxicology, including toxicology databases and computational models.
Key Reasons to Buy
- Understand the challenges ahead to overcoming the ADME/Tox bottleneck through a clear analysis of the short and long-term opportunities and their impact on pharmaceutical R&D.
- Recognize the need to integrate new and existing ADME/Tox models and testing strategies through a comprehensive review of currently accepted and emerging approaches to toxicology, from traditional animal studies to in vitro and in silico methods.
- Appreciate the imperative for radically new tools and paradigms to improve the predictive power of toxicology models through a detailed discussion of research activities aimed at developing, validating, and applying novel approaches.
- Gain insights into the issues and benefits associated with consortia approaches to toxicology via case studies of those already sharing data, technologies, expertise, and resources.
- Learn about ADME/Tox-related technology and business strategies through a thorough discussion of approaches taken by technology platform and pharmaceutical companies.
Key Topics Covered Include:
- Introduction: Industry Environment
- Technology Strategies
- Business Strategies
- A Case Study of Toxicity Impact--Product Withdrawals
- Company Profiles
Companies Mentioned Include: Acccelrys Inc. (a subsidiary of Pharmacopeia Inc.), Affymetrix, Inc., ArQule, Inc. (Camitro), Axaron Biosciences AG, Becton Dickinson, Cerep, Charles River Laboratories, Covance Inc., Curagen Corporation, Deltagen Corporation, Discovery Partners International, ExonHit Therapeutics SA, Gene Logic Inc., Iconix Pharmaceuticals Inc., Inveresk Research Group Inc., In Vitro Technologies, Inc., LeadScope Inc., LION Bioscience AG (Trega Biosciences), MDL Information Systems, Inc. (Elsevier Science, Inc.), Paradigm Genetics, Pharmagene Laboratories Limited, PHASE 1 Molecular Toxicology, Inc., Physiome Sciences, Inc., Xenogen Corporation.
